...
首页> 外文期刊>Channels >Ranolazine block of human Nav1.4 sodium channels and paramyotonia congenita mutants
【24h】

Ranolazine block of human Nav1.4 sodium channels and paramyotonia congenita mutants

机译:雷诺嗪阻断人Nav1.4钠通道和副肌强直先天突变体

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The antianginal drug ranolazine exerts voltage- and use-dependent block (UDB) of several Na~(+) channel isoforms, including?Na_(v)1.4. We hypothesized that ranolazine will similarly inhibit the paramyotonia congenita?Na_(v)1.4?gain-of-function mutations, R1448C, R1448H, and R1448P that are associated with repetitive action potential firing. Whole-cell Na~(+) current (I_(Na)) was recorded from HEK293 cells expressing the hNa_(v)1.4?WT or R1448 mutations. At a holding potential (HP) of -140 mV, ranolazine exerted UDB (10 Hz) of WT and R1448 mutations (IC_(50) = 59 - 71 μM). The potency for ranolazine UDB increased when the frequency of stimulation was raised to 30 Hz (IC_(50) = 20 - 27 uM). When the HP was changed to -70 mV to mimic the resting potential of an injured skeletal muscle fibre, the potency of ranolazine to block I_(Na) further increased; values of ranolazine IC_(50) for block of WT, R1448C, R1448H, and R1448P were 3.8, 0.9, 6.3, and 0.9 uM, respectively. Ranolazine (30 uM) also caused a hyperpolarizing shift in the voltage-dependence of inactivation of WT and R1448 mutations. The effects of ranolazine (30 uM) to reduce I_(Na) were similar (~35% I_(Na) inhibition) when different conditioning pulse durations (2-20 msec) were used. Ranolazine (10 μM) suppressed the abnormal I_(Na) induced by slow voltage ramps for R1448C channels. In computer simulations, 3 μM ranolazine inhibited the sustained and excessive firing of skeletal muscle action potentials that are characteristic of myotonia. Taken together, the data indicate that ranolazine interacts with the open state and stabilizes the inactivated state(s) of?Na_(v)1.4?channels, causes voltage- and use-dependent block of I_(Na) and suppresses persistent I_(Na). These data further suggest that ranolazine might be useful to reduce the sustained action potential firing seen in paramyotonia congenita.
机译:抗心绞痛药物雷诺嗪对几种Na〜(+)通道同工型包括?Na_(v)1.4具有电压依赖性和使用依赖性阻断(UDB)。我们假设雷诺嗪将同样抑制先天性副肌强直Na_(v)1.4?功能获得性突变R1448C,R1448H和R1448P,这些突变与重复动作电位激发有关。从表达hNa_(v)1.4ΔWT或R1448突变的HEK293细胞中记录全细胞Na〜(+)电流(I_(Na))。在-140 mV的保持电位(HP)下,雷诺嗪产生WT和R1448突变的UDB(10 Hz)(IC_(50)= 59-71μM)。当刺激频率提高到30 Hz(IC_(50)= 20-27 uM)时,雷诺嗪UDB的效力增加。当HP更改为-70 mV以模拟受伤的骨骼肌纤维的静息电位时,雷诺嗪阻断I_(Na)的能力进一步提高; WT,R1448C,R1448H和R1448P的雷诺嗪IC_(50)值分别为3.8、0.9、6.3和0.9 uM。雷诺嗪(30 uM)还引起WT和R1448突变失活的电压依赖性超极化转变。当使用不同的调节脉冲持续时间(2-20毫秒)时,雷诺嗪(30 uM)降低I_(Na)的效果相似(〜35%I_(Na)抑制)。雷诺嗪(10μM)抑制了R1448C通道的缓慢电压斜坡引起的异常I_(Na)。在计算机模拟中,3μM雷诺嗪抑制了强直肌特征性的骨骼肌动作电位的持续和过度放电。两者合计,数据表明雷诺嗪与开态相互作用并稳定Na_(v)1.4·通道的失活状态,引起I_(Na)依赖电压和使用的阻滞并抑制持久性I_(Na )。这些数据进一步表明,雷诺嗪可能有助于减少先天性肌强直中持续动作电位放电。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号